Country: আর্মেনিয়া
ভাষা: ইংরেজি
সূত্র: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
betamethasone (betamethasone 17-valerate), gentamicin (gentamicin sulfate)
Schering-Plough Labo N.V.
D07CC01
betamethasone (betamethasone 17-valerate), gentamicin (gentamicin sulfate)
1mg/g+ 1mg/g
cream
aluminium tube 30g
Prescription
Registered
2019-03-13
1. NAME OF THE MEDICINAL PRODUCT CELESTODERM.VCI WITH OARAMYCIN@ International nonproprietary name: betamethasone and antibiotics. 2. QUALITATIVE AND QUANTITATIVII COMPOSITION I g of cream contains active ingredients.' 1 g of cream contain s 1,220 nrg betamethasone valerate equivalent to I rng of betamethasone and gentamicin sulfate equivalent to I mg (1000 t.U.) of gentamicin. excipients: white soft paraffin, cetostearylalcohol, liquid paraffin, macrogol cetostearyl ether, sodium dihydrogen phosphate dihydrate, clilorocresol, phosphoric acid, sodium hydroxide/ phosphoric acid, purified water. 3. PIIARMACEUTICALFORM Cream. Description: homogeneous, white to off-white soft crearn without fbreign inclusions Pharmacotherapeutic group. Corticosteroids, dermatological preparations,r.Qorlicosteroids, combinations with antibiotics. 4. CLINICAL PARTICULARS -" . , ; ,;,';10';. d//} /. ol.,xot f , Treatment of skin diseases requiring treatment with a potent glucocorticoid in the presence of superinfection with gentam icin-suscepti ble organ i sms 4.2 Posology and method of administration Posolosy: Cream is applied 2'3 times daily. The frequency nray be reduced as the condition improves. Method of adminisration : A thin film of Cream should be applied to the affected areas of skin, The method of administration should be adjusted to the skin type and stage of the disease. Crearn is recommended in particular for greasy skin, weeping, itching, burning and seborrheic skin diseases, in acute stage. Duration of use: The duration of treatment with creafir should not exceed 7-10 days (7 days in children) because of the gentamicin content. As soon as rnedically confirmed that combined therapy is no longer necessary (i.e., either a dermatosis requiring a strong-acting gh.rcocorticoid or a superinfection with gentarnicin- susceptible organisms is no longer present), tleatment should be continued on the basis of single-agent therapy with a glucocorticoid (possib[y a weaker-acting glucocorticoid) or with an antibiotic. Mild cases usuall সম্পূর্ণ নথি পড়ুন